Targeted therapies can be used for AML with high heterogeneity in cellular genomic characteristics (Network et al., 2013), such as FLT3 inhibitors (such as midostaurin (Stone et al., 2017), quizartinib (Erba et al., 2023), sorafenib (Xuan et al., 2020), and gilteritinib (Perl et al., 2019; Pratz et al., 2020) for patients with FLT3-mutated AML, IDH1 inhibitors (ivosidenib (DiNardo et al., 2018) and olutasidenib (De Botton et al., 2023) for patients with IDH1-mutated AML, and IDH2 inhibitors (such as enasidenib (Stein et al., 2017) for patients with IDH2-mutated AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.